Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Background The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficacy outcomes and the relationship between patient baseline characteristics and treatment response. Methods This was a post hoc analysis of OSMO study data (GSK ID:204471; ClinicalTrials.gov No. NCT02654145). Patients with severe eosinophilic asthma uncontrolled by high-dose inhaled corticosteroids, other controller(s) and omalizumab subcutaneously (>= 4 months) were switched to mepolizumab 100 mg administered subcutaneously. Endpoints included the proportion of responders-i.e. patients achieving a pre-defined clinical improvement in >= 1 of the following outcomes: (1) Asthma Control Questionnaire (ACQ)-5 score (>= 0.5-points), (2) St George's Respiratory Questionnaire (SGRQ) total score (>= 4-points), (3) pre-bronchodilator forced expiratory volume in 1s (FEV1; >= 100 mL), all at Week 32, and (4) annualised rate of clinically significant exacerbations (>= 50% reduction). Results Of the 145 patients included, 94%, 83%, 63% and 31% were responders for >= 1, >= 2, >= 3 and 4 outcomes, respectively; 75% and 78% were ACQ-5 and SGRQ score responders, and 50% and 69% were FEV1 and exacerbation responders. Subgroup analyses demonstrated improvements irrespective of baseline blood eosinophil count, prior omalizumab treatment regimen/duration, comorbidities, prior exacerbation history, maintenance oral corticosteroid use, ACQ-5 and SGRQ scores, and body weight/body mass index. Conclusions After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in >= 1 clinical outcome. Improvements were observed regardless of baseline characteristics. Trial registration This manuscript is a post hoc analysis of data from the OSMO study. ClinicalTrials.gov, NCT02654145. Registered January 13, 2016.

Automated summary

The OSMO study showed that switching to mepolizumab resulted in beneficial responses in nearly all patients with uncontrolled severe eosinophilic asthma previously treated with omalizumab, regardless of baseline characteristics.